Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002
Stock Information for Capricor Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.